Autophagy is regulated by posttranslational modifications, including acetylation. Here we show that HLA-B-associated transcript 3 (BAT3) is essential for basal and starvation-induced autophagy in embryonic day 18.5 BAT3 −/− mouse embryos and in mouse embryonic fibroblasts (MEFs) through the modulation of p300-dependent acetylation of p53 and ATG7. Specifically, BAT3 increases p53 acetylation and proautophagic p53 target gene expression, while limiting p300-dependent acetylation of ATG7, a mechanism known to inhibit autophagy. In the absence of BAT3 or when BAT3 is located exclusively in the cytosol, autophagy is abrogated, ATG7 is hyperacetylated, p53 acetylation is abolished, and p300 accumulates in the cytosol, indicating that BAT3 regulates the nuclear localization of p300. In addition, the interaction between BAT3 and p300 is stronger in the cytosol than in the nucleus and, during starvation, the level of p300 decreases in the cytosol but increases in the nucleus only in the presence of BAT3. We conclude that BAT3 tightly controls autophagy by modulating p300 intracellular localization, affecting the accessibility of p300 to its substrates, p53 and ATG7.degradation | signalisation | nucleo-cytoplasmic shuttling A utophagy allows the lysosomal degradation of intracellular macromolecules and organelles after their sequestration in a vacuole known as the autophagosome (1). Basal autophagy is a cytoplasmic quality control mechanism that limits the production of reactive oxygen species and genomic instability. Autophagy is also induced to improve cell survival under stress.Signaling pathways involved in the regulation of autophagy have been widely studied (2). Autophagy is modulated at two levels: (i) the molecular machinery involved in autophagosome biogenesis, dependent on specific genes known as Atg (AuTophaGy) genes, and (ii) the upstream signaling pathways (e.g., PI3K, MAPK, mTOR) that act on ATG proteins. Posttranslational modifications are crucial for the regulation of autophagy. The first example came from Y. Oshumi's laboratory with the discovery of the conjugation systems for the ATG5-ATG12 and ATG8-phosphatidylethanolamine complexes in yeast (3). Phosphorylation is probably the most thoroughly investigated posttranslational event in autophagy. It appears that modulation of acetylation also affects Atg gene expression or activity; for instance, acetylation of the Unc-51-like kinase 1 (ULK1) (mammalian homolog of ATG1) by the acetylase Tat interacting protein 60 kDa (TIP60) induces autophagy after growth factor deprivation (4). In yeast, ESA1-dependent acetylation of ATG3 is essential for its interaction with ATG8 and ATG8 lipidation (5). Conversely, acetylation of ATG5, ATG7, microtubule associated protein 1 light chain 3 (LC3), and ATG12 by the acetyltransferase p300 inhibits autophagy (6), whereas their deacetylation by Sirtuins 1 (SIRT1) stimulates autophagy (7).HLA-B-associated transcript 3 (BAT3) is a nucleo-cytoplasmic shuttling protein that contains, among other, a nuclear export signal (NES) and...

Background:Cetuximab, a monoclonal antibody against EGFR used for the treatment of colorectal cancer (CRC), is ineffective in many patients. The aim of this study was to identify the signalling pathways activated by cetuximab in CRC cells and define new biomarker of response.Methods:We used in vitro, in vivo models and clinical CRC samples to assess the role of p38 and FOXO3a in cetuximab mechanism of action.Results:We show that cetuximab activates the MAPK p38. Specifically, p38 inhibition reduced cetuximab efficacy on cell growth and cell death. At the molecular level, cetuximab activates the transcription factor FOXO3a and promotes its nuclear translocation via p38-mediated phosphorylation, leading to the upregulation of its target genes p27 and BIM and the subsequent induction of apoptosis and inhibition of cell proliferation. Finally, we found that high FOXO3a and p38 expression levels are associated with better response rate and improved outcome in cetuximab-treated patients with CRC harbouring WT KRAS.Conclusions:We identify FOXO3a as a key mediator of cetuximab mechanism of action in CRC cells and define p38 as its activator in this context. Moreover, high FOXO3a and p38 expression could predict the response to cetuximab in patients with CRC harbouring WT KRAS.